Keyphrases
Aggressive Therapy
10%
Anti-apoptotic
10%
Anti-inflammatory Activity
10%
Biological Factors
10%
Cancer Cells
10%
Cancer Patients
10%
Endometrial Cancer
80%
Endometrial Cancer Recurrence
100%
Endometrioid Adenocarcinoma
100%
Estradiol
10%
Estradiol Hormone
10%
Estrogen Exposure
10%
Estrogen Level
10%
Estrogen Receptor
10%
Estrone
10%
Free IGF-I
10%
Growth Factors
80%
Gynecologic Malignancies
20%
Gynecologic Oncology Group
30%
Hazard Ratio
10%
Health Relevance
10%
High Stage
10%
High-to-Low
10%
Hyperinsulinemia
10%
IGF Axis
100%
IGF-I Level
10%
Immunohistochemistry
10%
Insulin
100%
Insulin Hormone
10%
Insulin Receptor
10%
Insulin-like
80%
Insulin-like Growth Factor 1 Receptor (IGF1R)
10%
Insulin-like Growth Factor 2 (IGF2)
30%
Insulin-like Growth Factor Binding Protein (IGFBP)
30%
Inverse Relation
10%
Most Common Form
10%
Novel Therapeutics
10%
Obese Patients
10%
Obesity
20%
Postmenopausal Women
10%
Precancerous
10%
Progesterone Hormone
10%
Progesterone Receptor
10%
Prognostic Value
10%
Prospective Cohort Study
10%
Public Health
10%
Quantitative PCR
10%
Receptor-based
10%
Recurrence Rate
10%
Recurrence Risk
10%
Recurring
20%
Residual Tumor
10%
Risk Factors
20%
Sequence Homology
10%
Serologic
10%
Serum Levels
10%
Sex Hormone-binding Globulin
10%
Sex Hormones
100%
Tissue Level
10%
Triage
10%
Tumor Expression
10%
Tumorigenic Pathway
10%
US Women
10%
Women's Health Initiative
10%
Medicine and Dentistry
Adenocarcinoma
100%
Antiapoptotic
10%
Antiinflammatory Activity
10%
Cancer
30%
Cross Sectional Study
10%
Diethylstilbestrol
20%
Estrogen Receptor
10%
Estrone
10%
Gynecological Oncology
30%
Hazard Ratio
10%
Hyperinsulinemia
10%
Immunohistochemistry
10%
Insulin Receptor
10%
Malignant Neoplasm
10%
Messenger RNA
10%
Neoplasm
20%
Postmenopause
10%
Progesterone
10%
Progesterone Receptor
10%
Prospective Cohort Study
10%
Prospective Study
20%
Public Health
10%
Recurrent Disease
100%
Reverse Transcription Polymerase Chain Reaction
10%
Sequence Homology
10%
Sex Hormone
100%
Sex Hormone Binding Globulin
10%
Somatomedin C
80%
Somatomedin C Receptor
20%
Triage
10%
Uterine Cancer
100%
Womens Health
10%
Pharmacology, Toxicology and Pharmaceutical Science
Adenocarcinoma
100%
Anti-Inflammatory Drug
10%
Antiapoptotic
10%
Cross-Sectional Study
10%
Diethylstilbestrol
20%
Endometrium Cancer
100%
Estrogen Receptor
10%
Estrone
10%
Hyperinsulinemia
10%
Immunoglobulin
10%
Insulin Receptor
10%
Malignant Neoplasm
10%
Messenger RNA
10%
Neoplasm
20%
Progesterone
10%
Progesterone Receptor
10%
Prospective Cohort Study
10%
Prospective Study
20%
Recurrent Disease
100%
Sex Hormone
100%
Sex Hormone Binding Globulin
10%
Somatomedin C
80%
Somatomedin C Receptor
20%